Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Ingrezza
Pharma
Neurocrine's Ingrezza guidance spooks investors
Neurocrine's stock price took a tumble Friday after the company revealed its 2025 revenue forecast for its tardive dyskinesia med Ingrezza.
Zoey Becker
Feb 10, 2025 9:13am
FDA approves Neurocrine's Crenessity for genetic adrenal disease
Dec 16, 2024 11:26am
Neurocrine elevates BD chief to succeed founder and CEO
May 29, 2024 11:42am
Neurocrine joins in on Tardive Dyskinesia Awareness Week
May 6, 2024 10:52am
Neurocrine's Ingrezza nabs Huntington's nod to rival Austedo
Aug 22, 2023 9:53am
Neurocrine gives up on Parkinson's drug Ongentys
May 3, 2023 10:55am
